Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Buy

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Neutral

B

Lumos Pharma, Inc. Common Stock (LUMO)

Pharmaceutical Preparations

https://www.lumos-pharma.com

Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

4200 MARATHON BLVD., SUITE 200
AUSTIN, TX

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/11/2011

Market Cap

26,008,302

Shares Outstanding

7,920,000

Weighted SO

7,914,582

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

PRDS --.--%

STTK --.--%

ELYM --.--%

CSBR --.--%

IPSC --.--%

SILO --.--%

PTIXW --.--%

RZLT --.--%

Beta

0.3010

Last Div

0.0000

Range

1.37-4.55

Chg

0.7514

Avg Vol

30267

Mkt Cap

26008302

Exch

NASDAQ

Country

US

Phone

512 215 2630

DCF Diff

2.9830

DCF

-0.0129

Div Yield

0.0000

P/S

17.5022

EV Multiple

-0.4165

P/FV

2.5276

Div Yield %

0.0000

P/E

-0.7265

PEG

-0.0325

Payout

0.0000

Current Ratio

4.2334

Quick Ratio

4.2334

Cash Ratio

3.4041

DSO

41.2651

DIO

0.0000

Op Cycle

41.2651

DPO

4100.1667

CCC

-4058.9015

Gross Margin

0.9798

Op Margin

-25.3170

Pretax Margin

-24.0572

Net Margin

-24.0572

Eff Tax Rate

-0.0189

ROA

-1.6740

ROE

-1.5799

ROCE

-2.2912

NI/EBT

1.0000

EBT/EBIT

0.9502

EBIT/Rev

-25.3170

Debt Ratio

0.2952

D/E

0.6135

LT Debt/Cap

0.3687

Total Debt/Cap

0.3802

Int Coverage

-54.6023

CF/Debt

-5.4707

Equity Multi

2.0783

Rec Turnover

8.8452

Pay Turnover

0.0890

Inv Turnover

0.0000

FA Turnover

3.2095

Asset Turnover

0.0696

OCF/Share

-4.2511

FCF/Share

-5.0923

Cash/Share

2.0707

OCF/Sales

-23.2079

FCF/OCF

1.1979

CF Coverage

-5.4707

ST Coverage

-113.4441

CapEx Coverage

-5.0530

Div&CapEx Cov

-5.0530

P/BV

2.5276

P/B

2.5276

P/S

17.5022

P/E

-0.7265

P/FCF

-0.6296

P/OCF

-0.7531

P/CF

-0.7531

PEG

-0.0325

P/S

17.5022

EV Multiple

-0.4165

P/FV

2.5276

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 20, 16:05 Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November GlobeNewswire Inc. Nov 07, 16:35 Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

Revenue Product Segmentation